Toward a Treat‐to‐Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement?
Authors' conclusion
This study provides real-world data for potential timelines to target with a treat-to-target strategy for JDM.
Study context
- Population
- Patients with physician-confirmed juvenile dermatomyositis (JDM) at two tertiary care centres, first two years after diagnosis (mean age at diagnosis 8 years)
- Participants
- 187 patients2 sites
- Exposure
- Gaslini (Gaslini) vs SickKids
- Outcome
- Time to treatment response (normalisation of muscle enzymes, muscle remission, skin remission, inactive disease)
- Follow-up
- First two years following diagnosis
Methodological detailstwo tertiary care centres, Kaplan-Meier survival analysis
- Two tertiary care centres
- Kaplan-Meier survival analysis
Main finding
As reported in the abstract
Time to treatment response
- Normalisation of muscle enzymes, on average, after treatment initiation
- three months
- Muscle remission, on average, after treatment initiation
- six months
- Skin remission, after starting treatment
- within 12 months
Observational data: associations, not effects.
Further findings
Time to inactive disease (varied between sites)
Original publication
Toward a Treat‐to‐Target Strategy in Juvenile Dermatomyositis: What Are the Suitable Targets and Optimal Timing of Their Achievement? Arthritis Rheumatol. Published 28 January 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →